Key result
Dabigatran etexilate emerges as a promising oral anticoagulant for preventing thromboembolism.
Why the study?
Does dabigatran etexilate prevent thromboembolism in patients at risk for venous or arterial thrombosis?
Population
Patients at risk for venous thromboembolism and arterial thrombosis, such as those undergoing orthopedic…
Design
Review
Authors
Loading...
May expand thromboembolism prevention options; leaves open need for randomized comparisons with established agents.
Does dabigatran etexilate prevent thromboembolism in patients at risk for venous or arterial thrombosis?
Dabigatran etexilate is highlighted as a promising oral direct thrombin inhibitor for the prevention of thromboembolism, offering an alternative to warfarin and heparins.
Nishio et al. (2008) conducted a review in Thromboembolism. Dabigatran etexilate was evaluated. Dabigatran etexilate is a promising new oral anticoagulant that offers greatly expanded therapeutic options for preventing thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: